SCHEMBL7225354

SCHEMBL7225354

O=C(O)c1cncc(CBr)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 6/20 0.57
POLB P06746 1/20 0.57
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 4/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
LMNA P02545 1/20 0.52
DDO Q99489 1/20 0.52
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
HTT P42858 3/20 0.42
GFER P55789 1/20 0.42
HSD17B10 Q99714 1/20 0.42
APP P05067 1/20 0.39
GAA P10253 1/20 0.39
HCAR3 P49019 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27697868 0.85 HCAR2 (0.53) HCAR2POLBALDH1A1KDM4EMEN1
SCHEMBL30777432 0.82 HCAR2 (0.59) HCAR2POLBALDH1A1KDM4EMEN1
SCHEMBL7817677 0.82 HCAR2 (0.59) HCAR2POLBALDH1A1KDM4EMEN1
SCHEMBL7674347 0.82 HCAR2 (0.53) HCAR2POLBALDH1A1KDM4EMEN1
SCHEMBL846393 0.80 CYP2C9 (0.61) HCAR2POLBALDH1A1KDM4EMEN1
SCHEMBL7471695 0.80 HCAR2 (0.57) HCAR2POLBALDH1A1KDM4EMEN1
SCHEMBL1244630 0.80 KDM4E (0.57) HCAR2POLBALDH1A1KDM4EMEN1
SCHEMBL30281282 0.80 CYP2C9 (0.61) HCAR2POLBALDH1A1KDM4EMEN1
SCHEMBL3938261 0.78 ATM (0.59) ALDH1A1KDM4ECYP2C9CYP2C19HTT
SCHEMBL51830 0.78 HCAR2 (0.70) HCAR2POLBALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111116579-B Synthesis method of nicergoline 江苏汉斯通药业有限公司 2021-04-27 CN claimed
CN-111116579-A Synthesis method of nicergoline 江苏汉斯通药业有限公司 2020-05-08 CN claimed
EP-4486453-A1 BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2025-01-08 EP disclosed
CN-118843616-A Benzamide compounds for the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-10-25 CN disclosed
WO-2024124287-A1 COMPOUNDS FOR TREATING VIRAL INFECTION THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2024-06-20 WO disclosed
WO-2023166103-A1 BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2023-09-07 WO disclosed
CN-113480532-B Synthesis method of nicergoline 福安药业集团重庆博圣制药有限公司 2022-08-16 CN disclosed
CN-113480532-A Synthesis method of nicergoline 福安药业集团重庆博圣制药有限公司 2021-10-08 CN disclosed
CN-111116579-B Synthesis method of nicergoline 江苏汉斯通药业有限公司 2021-04-27 CN disclosed
EP-3768264-A1 AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE Virginia Commonwealth University (US) 2021-01-27 EP disclosed
CN-111116579-A Synthesis method of nicergoline 江苏汉斯通药业有限公司 2020-05-08 CN disclosed
WO-2019182938-A1 AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE VIRGINIA COMMONWEALTH UNIVERSITY (US) 2019-09-26 WO disclosed
CN-101610761-A 1-amino methyl-L-phenyl-cyclohexane-derivant as the DDP-IV inhibitor NOVARTIS AG (CH) 2009-12-23 CN disclosed
CN-101102796-A Benzothiazole formulations and uses thereof ARES TRADING SA (CH) 2008-01-09 CN disclosed
CN-101061105-A Potentiators of glutamate receptors LILLY CO ELI (US) 2007-10-24 CN disclosed
US-6624188-B1 Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and ALLERGAN, INC. 2003-09-23 US disclosed
US-5324840-A Skin disorders ALLERGAN, INC. (US) 1994-06-28 US disclosed